Background. Due to the involvement of opioids and benzodiazepines in rising pharmaceutical overdoses, a reduction in coprescribing of these medications is a national priority, particularly among patients with substance use disorders and other high-risk conditions. However, little is known about primary care (PC) and mental health (MH) prescribers' perspectives on these medications and efforts being implemented to reduce coprescribing.
highlight agreement, disagreement, and neutrality and summarized with means and percentages.
Results. Over 80% of both prescriber groups reported concern about concurrent use and > 75% strongly agreed with clinical practice guidelines (CPG) that recommend caution in coprescribing among patients with high-risk conditions. More than 40% of both prescriber groups indicated that coprescribing continues because of beliefs that patients appear stable without adverse events and tapering/discontinuation is too difficult. Over 70% of prescribers rated strategies for addressing patients who refuse to discontinue, more time with patients, and identification of high-risk patients as helpful in reducing coprescribing.
Conclusion. Despite strong agreement with CPGs, prescribers reported several barriers that contribute to coprescribing of opioids and benzodiazepines and challenge their ability to taper these medica
Introduction
Despite clinical practice guidelines (CPG) that discourage opioid analgesic and benzodiazepine coprescribing, 27% of veterans enrolled in VA care who are prescribed opioids are also prescribed benzodiazepines [1] . Opioids and benzodiazepines are the most common prescription classes involved in pharmaceutical overdoses, with opioids implicated in 75.2% and benzodiazepines in 29.4% of all pharmaceutical overdoses in 2010. Further, benzodiazepines were involved in 30% of opioid-related overdoses in 2011 [2] . For those with problematic alcohol or drug use, suicide risk, or impaired breathing-related conditions such as sleep apnea [3, 4] , as well as the elderly (age 65), the potentially lethal risks associated with concurrent use of these medications may be even greater [5] [6] [7] [8] .
As a result of the substantial increase in unintentional drug overdose fatalities involving opioid analgesics and benzodiazepines over the last decade [9] , the VA has prioritized an overall reduction in nonrecommended opioid prescribing practices, including concurrent use of opioids and benzodiazepines [10] . Conceptual frameworks of implementation strategies in health services such as the Promoting Action on Research Implementation in Health Services (PARIHS) model highlight the importance of assessing prescribers' knowledge and experience of evidence in support of the recommended practices and the receptivity of the setting to adopting such practices [11] . Given that in the VA, most opioids are prescribed in primary care, while the majority of benzodiazepines are prescribed in mental health clinics [12] , obtaining the perspectives of prescribers from both settings is critical. Although prior studies have identified primary care prescribers' attitudes and practices regarding the use of opioids or benzodiazepines separately, little is known about primary care and mental health prescribers' perspectives on concurrent use of these medications and, in particular, on efforts to reduce coprescribing of opioids and benzodiazepines.
Very little information is available on factors that may facilitate reductions in opioid prescribing. However, provider-identified concerns regarding opioid use for the management of chronic pain may prove helpful in facilitating adherence to guideline recommendations. With regards to opioids, prescribers have expressed several concerns, including potential for addiction [13] [14] [15] , potential for abuse or misuse [13] [14] [15] [16] , diversion [15, 16] , and patient harm from adverse effects [17] . Barriers to tapering or discontinuing opioids include lack of prescriber awareness regarding prescribing guidelines [17] , threats to provider/patient relationship [16] , and additional workload or insufficient time [17] . With regards to the use of benzodiazepines, prior research has identified factors that facilitate adherence to guideline recommendations, including prescribers' concerns about the potential for abuse or dependence, concerns about negative consequences, and beliefs that cessation will bring benefits [18, 19] . Barriers to recommended benzodiazepine prescribing practices identified in prior studies are numerous and have included limited availability of effective alternatives [19] [20] [21] [22] , few side effects observed by providers [23] [24] [25] , negative impact on provider/patient relationship [21] , limited time [19, 20] , perception that discontinuation is harsh [19, 20] , futility of discontinuation/tapering [20] , and expected resistance from patients [19] .
This project consists of an anonymous survey of primary care (PC) and mental health (MH) prescribers at one large VA health care system and is the first phase of a larger quality improvement project to evaluate the implementation of an advanced medication alert designed to identify patients who are coprescribed opioids and benzodiazepines and who have comorbid substance use or other high risk conditions. Primary goals of this survey include identification of factors affecting implementation of the medication alert and reductions in opioid and benzodiazepine coprescribing. To address these goals, we assessed PC and MH prescribers' beliefs regarding 1) CPG recommendations discouraging opioid and benzodiazepine coprescribing among patients with substance use and other high-risk conditions; 2) the effect of these medications on patient functioning and quality of life; 3) barriers to tapering or discontinuing concurrent use of these medications; and 4) prescribers' perspectives on medication alerts.
Methods

Conceptual Framework for Evaluating Implementation
The PARIHS model was selected as the theoretical framework to guide survey development, as well as the overall evaluation of the implementation of the medication alert [26] . The PARIHS framework was selected for its multidimensional focus on the complexities of implementing evidence into practice [26] and because it has been adapted for evidence-based practice implementation efforts in the VA [27, 28] . The PARIHS framework proposes that successful implementation is a function of three interacting elements-the strength of the evidence supporting the intervention, the quality of the implementation context, and the facilitation of the change process [29] . Survey items focused on the evidence and context domains of the PARIHS model and assessed prescribers' perceptions of the evidence associated with the risks of coprescribing opioids and benzodiazepines, their overall receptivity to the medication alert and the goal of reducing concurrent use of opioid and benzodiazepines, and contextual factors that may potentially affect the adoption of the medication alert and modification of prescribers' prescribing practices.
Setting
The VA Puget Sound Health Care System (VAPSHCS) is a multisite health care system that includes two medical centers, one in Seattle and one in American Lake, and seven community-based outpatient clinics (including clinics staffed by contracting services rather than VA employees) providing care to over 80,000 veterans living in the Pacific Northwest. This project, including development and approval of the medication alert, was a partnership between several VAPSHCS services, including mental health, primary care, pharmacy, and specialtypain, and the VA central office, with a primary goal of improving the quality and safety of clinical care; therefore, the project was considered a quality improvement evaluation and did not require human subjects' approval from the VAPSHCS Institutional Review Board.
Sample
All prescribers working in PC and MH settings (including specialty mental health and substance use disorder services) were eligible to participate in this project. Utilizing pharmacy data extracted from the VA Northwest Veterans Integrated Service Network (VISN 20) data warehouse, we identified providers who ordered at least one opioid and/or benzodiazepine prescription between January 1, 2014, and March 31, 2014. This list was confirmed with leaders from eligible clinics. The final sample of eligible prescribers included 114 PC and 67 MH prescribers, all of whom were invited to complete the electronic survey anonymously.
Survey Development
The PARIHS model was used to develop a 30-item survey (Appendix A) organized into 10 content domains. Table 1 provides an overview of the content domains and the associated questions on the survey. A 5-point Likert scale was used for most questions and included response options 1) not at all/never/extremely negative, 2) slightly/rarely/negative, 3) moderately/sometimes/neither disagree or agree, 4) quite a bit/often/positive or 5) extremely/always/extremely positive. Several questions included an "If other, please specify" option for respondents to provide narrative responses. Results of these responses will be analyzed and presented in a subsequent manuscript. The survey was pilot-tested by two PC and two MH prescribers for clarity, wording, and content. Prior to piloting the survey, testers were instructed to measure the time required to complete the survey and to identify questions that were poorly worded, unclear, or redundant. After piloting the survey, the lead author briefly interviewed each tester to identify questions that could be deleted, revised to improve clarity, or added to address content, with responses used to iteratively revise the survey.
Survey Distribution
The anonymous electronic survey was distributed to PC and MH prescribers across VAPSHCS using an individualized e-mail with an embedded survey link from April through June 2014. Following the initial e-mail, three subsequent e-mail messages were sent at 1-week intervals to all prescribers as reminders to complete the survey.
Data Analysis
We first examined the data to determine whether the age and gender of survey respondents were representative of the age and gender of all of the prescribers who were invited to participate in the survey. Questions regarding age and gender were included on the survey, and for the full sample of invited participants, age and gender were obtained from the VISN 20 data warehouse. To identify perspectives of respondents that reflected agreement, disagreement, or neutrality, we collapsed the ends of the response sets. For example, for items with the response set "not at all," "slightly," "moderately," "quite a bit," and "extremely," responses were collapsed to "not at all or slightly," "moderately," and "quite a bit or extremely." Descriptive statistics were used to summarize responses, with means calculated for continuous variables and percentages for categorical variables. Chi-square statistics were used to compare responses of PC and MH prescribers. Responses to item 23 were not analyzed because of an error in the response set for this item. All analyses were conducted using Stata MP, version 14 [30] . Table 2 shows the demographic characteristics of the PC and MH participants who responded to the survey. Overall, 55 of 115 (47.8%) PC and 31 of 67 (46.3%) MH prescribers responded to the survey. The prescriber groups were similar with respect to age and gender, with women representing over half of both PC and MH prescribers. A large majority of both the PC and MH prescribers were white. MH prescribers had more years in practice in the VA compared with PC prescribers. Physicians represented the most common discipline in both prescriber groups, followed by nurse practitioners.
Results
Participant Characteristics
There were no meaningful differences by gender (PC, women: 54.6% vs 58.6%; MH, women: 51.6% vs 47.7%) or age (PC: 51.6 vs 51.8 years; MH: 51.2 vs 52.8 years) among those who responded to the survey and the full sample of those who were invited to complete the survey. [32] as very good to excellent (31.5% vs 19.4%, P < 0.05), with only 11.1% of PC and 16.1% of MH prescribers reporting that they had not seen the clinical practice guidelines, and 3.7% of PC and 25.8% of MH prescribers reporting very poor to poor ratings of their knowledge. Nineteen percent of PC and 12.9% of MH prescribers reported very good to excellent knowledge of the VA Pharmacy Benefit Management Services clinical guidance for insomnia treatments [33] . In contrast, 31.5% of PC and 22.6% of MH prescribers rated their knowledge of this guidance as very poor to poor, and 20.4% of PC and 38.7% of MH prescribers reported that they had never seen the clinical guidance on insomnia. Table 3 shows that most PC and MH respondents reported strong concerns about prescribing opioids for patients who are also prescribed benzodiazepines and about prescribing benzodiazepines for patients who are also prescribed opioids. Most PC and MH prescribers also agreed with clinical practice guidelines that recommend caution in the coprescribing of opioids and benzodiazepines among patients with substance use disorders, high suicide risk, sleep apnea, and ages 65.
Beliefs That Contribute to Continuation of Opioid and Benzodiazepine Coprescribing
PC and MH prescribers endorsed many reasons for opioid and benzodiazepine coprescribing (Table 4) . Beliefs endorsed most often among PC and MH prescribers as often/always contributing to coprescribing included tapering/discontinuing would be too difficult (47.2% and 61.3%, respectively), not enough time to negotiate discontinuing or tapering with patients (50.0% and 48.4%, respectively), and patients are stable on these medications with no adverse effects (43.3% and 50.0%, respectively). Although endorsed less often, 34.0% of PC and 45.2% of MH prescribers also indicated that when the medications were prescribed by different prescribers, it was often/always too difficult to coordinate with the other prescriber to taper/discontinue one or both of the medications. MH prescribers were nearly two times more likely than PC prescribers to endorse the belief that the benefits of opioids and benzodiazepines often/always exceed the risks (41.9% vs 21.6%, respectively, ns) and the belief that discontinuation of these medications often/always causes suffering (54.8% vs 26.9%, respectively, P < 0.05).
Beliefs Regarding Patient Functioning and Quality of Life
Figure 1a presents prescribers' responses to questions regarding a patient's functioning (e.g., physical and psychosocial functioning) and quality of life (e.g., health and happiness) while coprescribed opioids and benzodiazepines. Responses to the question about typical outcome for patient functioning were spread somewhat evenly across negative/extremely negative, positive/extremely positive, and no change response options. A substantial minority, 15.4% of PC and 22.6% of MH prescribers, were not sure about the functioning of these patients. Prescribers' responses regarding the typical outcome for patient quality of life were more varied, with no change (34.6%) the most common rating among PC prescribers and equal endorsement of negative/extremely negative and positive/extremely positive (32.3% and 32.3%, respectively) among MH prescribers. The response not sure was indicated by 11.5% of PC and 22.6% of MH prescribers. Figure 1b shows prescribers' responses to the questions about changes in patient functioning when long- 
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term opioid or benzodiazepine therapy is discontinued. Approximately one-third of respondents from both groups rated the typical change in patient functioning after discontinuing long-term opioid therapy as positive to extremely positive, with another one-third of both groups rating the change as negative to extremely negative. Of note, 2 in 10 MH prescribers were not sure about the typical patient's functioning after discontinuation of long-term opioid therapy.
Responses were similar to the question about changes in patient functioning after discontinuation of long-term benzodiazepine therapy, with an equal percentage (30.8%) of PC prescribers rating the typical change in functioning as negative/extremely negative and positive/extremely positive. For MH prescribers, the most frequent response was negative/extremely negative (41.9%), followed by positive/extremely positive (29.0%). Further, 17.3% of PC and 19.4% of MH prescribers were not sure about the typical change in functioning after discontinuation of long-term benzodiazepine therapy. Table 5 shows resources that prescribers indicated would be helpful in efforts to reduce concurrent use of opioids and benzodiazepines. Of all of the resources, a need for approved strategies to guide interactions with patients who refuse to consider discontinuation of opioid and/or benzodiazepine medications was rated quite to extremely helpful by more than 80% of both prescriber groups. Access to alternative behavioral interventions, more time with patients, and identification of patients who are coprescribed these medications were rated as quite to extremely helpful by more than 70% of both prescriber groups. Firm policies that support decisions to discontinue opioid and/or benzodiazepine medications and improved communication between prescribers in cases where medications are prescribed by multiple prescribers were rated quite to extremely helpful by more than 60% of prescribers. PC prescribers 
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Beliefs About Medication Alerts
As shown in Table 6 , both PC and MH prescribers held positive views of medication alerts, with > 70% agreeing/strongly agreeing that medication alerts can identify patient risks that might otherwise go unnoticed, prevent serious adverse outcomes, and help providers prescribe more safely. Less than one-quarter of both prescriber groups agreed or strongly agreed that medication alerts waste more time than they save, while even fewer (< 20%) agreed or strongly agreed with a statement indicating they ignore medication alerts.
Discussion
Despite the rising rates of opioid overdose in the United States over the last decade and the contribution of benzodiazepines to this trend, there is surprisingly little information about the perspectives of PC and MH providers, who often prescribe these medications and are increasingly being expected to change such prescribing practices. This survey, designed to assess the knowledge, beliefs, and experiences of PC and MH providers prior to the implementation of an advanced medication alert, found that both prescriber groups were concerned about the concurrent use of opioids and benzodiazepines among their patients and agreed with clinical practice guidelines that recommend caution in prescribing these medications among those diagnosed with substance use disorders, sleep apnea, and suicide risk, and those aged 65 and older. Furthermore, survey results suggest there is a culture in prescribers' clinics or patient-aligned care teams to discuss the risks of these medications and encourage alternative treatments. Several beliefs identified in the survey suggest that coprescription persists because of logistical or resource constraints, such as the difficulty of tapering/discontinuing and lack of time to discuss a taper. However, substantial minorities of prescribers also note their clinical experience as contributing to coprescribing of these medications, including that the benefits of opioids and benzodiazepines outweigh the risks, that patients have tolerated these medications without prior adverse events, and that discontinuation would cause patients to suffer. Providers' opinions regarding the functioning and quality of life of patients coprescribed these medications, as well as those discontinued from the medications, are clearly mixed, with similar percentages of prescribers reporting improved, worsened, and no change in or uncertainty about patients' status. Over 70% of prescribers identified a need for approved strategies for treating patients who refuse to consider discontinuation of opioids and/or benzodiazepines, medication and behavioral alternatives, more time with patients, and identification of patients who are prescribed these medications in combination to assist in their efforts to reduce coprescribing of opioids and benzodiazepines.
Overall, beliefs about medication alerts were largely favorable, with most prescribers agreeing or strongly agreeing with the ability of medication alerts to identify patients at risk of adverse events and promote safe prescribing.
Many of the most common beliefs identified in this project as contributing to the continued coprescribing of opioids and benzodiazepines have been reported in prior studies assessing prescribers' perspectives of opioid or benzodiazepine medications. For instance, limited prescriber time [18, 20, 34, 35] and beliefs that tapering/ discontinuation is too difficult [18, 20, 35, 36] have been reported as factors contributing to providers continuing medications in the opioid, benzodiazepine, and polypharmacy literature, as has the belief that coprescribing is safe and effective for patients receiving stable doses over extended periods [20, 35] . In our sample, a significant minority of prescribers also identified a lack of information on medication and behavioral alternatives to opioids and benzodiazepines. This belief is not often reported in the literature and might be relatively easy to address with additional education focused on the clinical efficacy and local availability of behavioral treatments for chronic pain [37] , anxiety [38] , and sleep disorders [39] . Another less commonly reported finding in the polypharmacy literature identified by this project is prescribers' belief that it is too difficult to coordinate a plan to discontinue or taper when the medications are prescribed by different prescribers. As opioids and benzodiazepines are often prescribed by different prescribers in the VA, this poses a considerable challenge to reducing this medication combination without strategies that facilitate prescriber communication.
Our finding that one-third of prescribers in both settings rated the typical outcomes for patient functioning and quality of life as positive to extremely positive for patients who are coprescribed opioids and benzodiazepines suggests that a substantial minority of prescribers may hold complex views about the therapeutic benefits and potential harms associated with these medications. For instance, prescribers may agree in principle with the clinical practice guidelines and research findings recommending caution, but in their clinical experience have observed the benefits of these medications to exceed the potential risks among patients they treat with the medication combination. Because changing the prescribing practices of this subset of prescribers is likely to be challenging without identifying the reasons such a view is held, further research is needed to identify the specific beliefs and clinical experiences that contribute to the understanding that this medication combination improves functioning and quality of life. It is also possible that coprescribing is considered clinically justifiable under certain conditions, such as when treatment is of limited duration or palliative, or the prescriber intends to closely monitor the patient for adverse events [40] . Changing nonrecommended opioid and benzodiazepine prescribing practices will be further complicated by the nearly one-third of PC and MH prescribers who rated the change in functioning of a typical patient to be negative or extremely negative after discontinuing long-term opioid or benzodiazepine therapy. Doubt about the benefits of discontinuing long-term opioid or benzodiazepine treatment among these PC and MH prescribers represents a significant barrier to reducing coprescribing. Somewhat surprisingly, more than 1 in 10 PC and approximately 1 in 5 MH prescribers were not sure about the typical patient functioning and quality of life outcomes of patients who are coprescribed these medications. Our survey was not able to identify the source of these prescribers' uncertainty, but it may be due to a lack of time or experience to measure such outcomes, difficulty in recalling the typical outcomes of patients, witnessed variation in outcomes, or concerns about the validity of patient-reported functioning or quality of life.
As traditional education approaches such as passive dissemination of materials and educational meetings alone are minimally effective [41] , multifaceted interventions such as medication alerts or reminders [42] , audit, and feedback [43, 44] may also be necessary to effect change in this subset of prescribers. Our findings also suggest that health care systems will likely need to increase access to medication and behavioral alternatives to opioids and benzodiazepines and present additional information about their effectiveness to facilitate clinical decision making.
Consistent with studies on determinants of prescribing, prescribers' responses to our survey suggest patients' expectations and demands influence their prescribing practices as well [34, 45, 46] . Nearly half of prescribers reported there was not enough time to negotiate discontinuing or tapering of opioid and benzodiazepine medications with patients who expect to continue receiving them. Furthermore, nearly 90% of all prescribers rated a need for approved strategies to address the challenge that occurs when patients refuse to consider discontinuation of opioids and/or benzodiazepines, a barrier not explicitly identified in the opioid, benzodiazepine, or polypharmacy literature. However, a concern that is commonly reported in the opioid and benzodiazepine literature is the effect that prescribing decisions can have on the provider-patient relationship [16, 21, 35] . Denying patients the medications they expect or have been prescribed long-term, particularly if the decision appears prescriber driven, may have a detrimental effect on the prescriber-patient relationship and represent a source of prescribers' frustration and burnout [16] . Such strong endorsement for the need for approved strategies may reflect prescribers' belief that patients' frustration or hostility would be less impactful to the relationship if decisions to deny or discontinue their medications were supported by policies of the larger health care system. A healthy provider-patient relationship is the cornerstone of health care, the means by which information is gathered, diagnoses and treatment plans are developed, and treatment progress or outcomes are assessed [47] . Thus, identification of clinical strategies to repair or prevent ruptures in the providerpatient relationship is an important area for research. Qualitative data collection approaches provide opportunities to obtain in-depth information that are likely needed to advance our understanding of patients' and providers' concerns and reactions to these challenging health encounters. A subsequent stage of this larger quality improvement project included semistructured interviews with prescribers, and analyses of these data are currently underway.
With few exceptions, most of the commonly reported beliefs and helpful resources were reported consistently across both prescriber groups. However, MH prescribers were two times more likely than PC prescribers to identify the belief that the benefits of opioids and benzodiazepines exceed their risks and the belief that discontinuing or tapering these medications will cause patients to suffer. In contrast, PC prescribers were more likely to identify access to alternative medication interventions and consultation with experts as quite/extremely helpful. Such differences speak to the need to be mindful of differences in clinical experiences across prescriber groups and to tailor interventions appropriately.
Several of the study's findings suggest changes in policy may be needed at the organization level to assist providers' efforts to reduce nonrecommended coprescribing practices. Patient expectations can shape provider-patient interactions and lead to dissatisfaction and distrust among patients if they are not met, especially if providers are perceived as responsible [48, 49] . According to attribution theory, patients attribute changes in prescribing behaviors to either the prescriber (internal) or to the situation (external) [50] . For instance, prior research has found that patients who are dissatisfied with restrictions on their opioid medications tended to attribute the cause to their prescribers, whereas those who are not dissatisfied by such restrictions tended to attribute the changes to factors external to the prescriber (e.g., potential harm caused by medications) [49] . Although prescribers may benefit from additional training to negotiate these difficult interactions, another approach might be to shift the reason for tapering these medication classes from the provider to the health care organization through formal clinical policy. In this context, prescribers are less likely to become the target of patients' frustration and dissatisfaction. Furthermore, for the more complex and challenging interactions with patients, the time restrictions created by brief visits typical of most health care systems can lead to diminished satisfaction among patients and burnout among providers [16] . Traditional time for health encounters may have to be extended to allow for a full discussion of patients' concerns, risks of these medication classes, and pharmacological and behavioral alternatives. Changes to these policies may be particularly helpful for providers who are tasked with tapering opioids and/or benzodiazepines and who have limited history with patients who have been coprescribed these medications long-term by another provider.
Our finding that communication is difficult between prescribers of these medications is part of larger communication problem observed in health care. Communication failures have been identified as the leading cause of harm to patients by the Joint Commission [51] . Several barriers potentially contribute to breakdowns in health care communication, including differences in communication styles [52] , uncertainty about which provider is ultimately responsible for a patient's care [53] , and lack of standardized communication practices [54] . While strategies to improve efficient communication and reduce adverse events have been found to be effective in various health care settings [55] [56] [57] [58] , additional work is needed by researchers and/or quality improvement experts to assess whether such strategies lead to meaningful improvements in communication among outpatient PC and MH prescribers.
Our quality improvement project has several limitations. Data were obtained from prescribers at one VA health care system, limiting the generalizability of survey results to other VA or non-VA facilities. Overall, the survey response rate of 47% is low, resulting in potential for response bias. Though no meaningful gender or age differences were noted between those who were invited to participate and those who completed a survey, it is possible that other important differences were not detected. The small sample size may have limited our ability to detect differences between PC and MH prescribers. Furthermore, the survey was developed specifically for the project and has not been validated. Information collected from prescribers was limited by the survey's response options; thus, it may lack the detail and depth of information collected by alternative approaches.
Conclusion
Although most prescribers had concerns about concurrent opioid and benzodiazepine use and agreed with clinical guidelines recommending caution in coprescribing medications in patients with comorbid risk conditions, they endorsed several factors that contribute to coprescribing of opioids and benzodiazepines, as well as barriers to discontinuing/tapering these medications. Perspectives on medication alerts, which have the potential to efficiently identify patients who are coprescribed these medications, were mostly favorable. However, nearly one-third of both prescriber groups view more harm than benefit from discontinuing longterm opioid and benzodiazepine therapies, suggesting that for some patients and prescribers, changing practice will likely require multifaceted interventions. While plans to taper any medication must take the circumstances and health of the individual patient into account in both the timing and rate of the taper and should not be applied simply as an automatic response to all patients because of organizational policy, health care systems' policies that place formal restrictions on coprescription of opioids or benzodiazepines may aid prescribers' efforts to reduce coprescribing, while simultaneously maintaining the trust of their patients.
